Docosahexaenoic Acid Modulates a HER2-Associated Lipogenic Phenotype, Induces Apoptosis, and Increases Trastuzumab Action in HER2-Overexpressing Breast Carcinoma Cells

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Ravacci, Graziela Rosa ^a   Brentani, Maria Mitzi ^a   Tortelli, Tharcisio Citrângulo ^a   Torrinhas, Raquel Suzana M M ^a   Santos, Jéssica Reis ^a   Logullo, Angela Flávia ^b   Waitzberg, Dan Linetzky ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CD36 ANTIGEN; COMPLEMENTARY DNA; DIACYLGLYCEROL ACYLTRANSFERASE 1; DOCOSAHEXAENOIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID; FATTY ACID BINDING PROTEIN 4; MAMMALIAN TARGET OF RAPAMYCIN; MEDULLIPIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RNA; S6 KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRASTUZUMAB; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG INHIBITION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LIPOGENESIS; NUCLEAR REPROGRAMMING; PHENOTYPE; PSEUDOCOWPOX VIRUS; BREAST TUMOR; DRUG EFFECTS; FEMALE; METABOLISM; TUMOR CELL LINE;

ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOCOSAHEXAENOIC ACIDS; FEMALE; HUMANS; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84948468022     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/838652     Document Type: Article

References (55)

1. J. A. Menendez and R. Lupu, "Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis," Nature Reviews Cancer, vol. 7, no. 10, pp. 763-777, 2007.
2. J. A. Menendez, "Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives," Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1801, no. 3, pp. 381-391, 2010.
3. M. Hilvo, C. Denkert, L. Lehtinen et al., "Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression," Cancer Research, vol. 71, no. 9, pp. 3236-3245, 2011.
4. M. T. E. Montales, O.M. Rahal, H. Nakatani, T. Matsuda, and R. C. M. Simmen, "Repression of mammary adipogenesis by genistein limits mammosphere formation of human MCF-7 cells," Journal of Endocrinology, vol. 218, no. 1, pp. 135-149, 2013.
5. C. Nieva, M. Marro, N. Santana-Codina, S. Rao, D. Petrov, and A. Sierra, "The lipid phenotype of breast cancer cells characterized by Raman microspectroscopy: towards a stratification of malignancy," PLoS ONE, vol. 7, no. 10, Article IDe46456, 2012.
6. S. M. Tovey, S. Brown, J. C. Doughty, E. A. Mallon, T.G. Cooke, and J. Edwards, "Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours," British Journal of Cancer, vol. 100, no. 5, pp. 680-683, 2009.
7. J. Arribas, J. Baselga, K. Pedersen, and J. L. Parra-Palau, "p95HER2 and breast cancer," Cancer Research, vol. 71, no. 5, pp. 1515-1519, 2011.
8. A. Bollig-Fischer, M. Dziubinski, A. Boyer, R. Haddad, C. N. Giroux, and S. P. Ethier, "HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation," Cancer Research, vol. 70, no. 20, pp. 7862-7873, 2010.
9. R. Ghosh, A. Narasanna, S. E. Wang et al., "Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers," Cancer Research, vol. 71, no. 5, pp. 1871-1882, 2011.
10. J. C. Singh, K. Jhaveri, and F. J. Esteva, "HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development," British Journal of Cancer, vol. 111, pp. 1888-1898, 2014.
11. Y. Wu, X. Shang, M. Sarkissyan, D. Slamon, and J. V. Vadgama, "FOXO1A is a target for HER2-overexpressing breast tumors," Cancer Research, vol. 70, no. 13, pp. 5475-5485, 2010.
12. T. Ichikawa, F. Sato, K. Terasawa et al., "Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells," PLoS ONE, vol. 7, no. 2, Article ID e31422, 2012.
13. A. B. Zelnak, P. Nikolinakos, J. Srinivasiah et al., "High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy," Clinical Breast Cancer, vol. 15, no. 1, pp. 31-36, 2015.
14. 2014, http://www.gene.com/download/pdf/herceptin prescribing.pdf.
15. G. R. Ravacci, M. M. Brentani, T. Tortelli et al., "Lipid raft disruption by docosahexaenoic acid induces apoptosis in transformed human mammary luminal epithelial cells harboring HER-2 overexpression," Journal of Nutritional Biochemistry, vol. 24, no. 3, pp. 505-515, 2013.
16. P. Nagy, G. Vereb, Z. Sebestyén et al., "Lipid rafts and the local density of ErbB proteins influence the biological role of homoand heteroassociations of ErbB2," Journal of Cell Science, vol. 115, no. 22, pp. 4251-4262, 2002.
17. M.-M. Mocanu, Z. Fazekas, M. Petrás et al., "Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (trastuzumab) resistant and sensitive tumor cell lines," Cancer Letters, vol. 227, no. 2, pp. 201-212, 2005.
18. D. C. Márquez, H.-W. Chen, E. M. Curran, W. V. Welshons, and R. J. Pietras, "Estrogen receptors in membrane lipid rafts and signal transduction inbreast cancer," Molecular and Cellular Endocrinology, vol. 246, no. 1-2, pp. 91-100, 2006.
19. Q. Jin, L. X. Yuan, D. Boulbes et al., "Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells," Breast Cancer Research, vol. 12, article R96, 2010.
20. S. Hardy, Y. Langelier, and M. Prentki, "Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects," Cancer Research, vol. 60, no. 22, pp. 6353-6358, 2000.
21. R. T. Brookheart, C. I. Michel, and J. E. Schaffer, "As a matter of fat," Cell Metabolism, vol. 10, no. 1, pp. 9-12, 2009.
22. A. Kourtidis, R. Srinivasaiah, R. D. Carkner, M. J. Brosnan, and D. S. Conklin, "Peroxisome proliferator-activated receptor- γ protects ERBB2-positive breast cancer cells from palmitate toxicity," Breast Cancer Research, vol. 11, article R16, 2009.
23. H. N. Bagley, Y. Wang, M. S. Campbell, X. Yu, R.H. Lane, and L. A. Joss-Moore, "Maternal docosahexaenoic acid increases adiponectin and normalizes IUGR-induced changes in rat adipose deposition," Journal of Obesity, vol. 2013, Article ID 312153, 7 pages, 2013.
24. N. Siriwardhana, N. S. Kalupahana, M. Cekanova, M. Le Mieux, B. Greer, and N. Moustaid-Moussa, "Modulation of adipose tissue inflammation by bioactive food compounds," Journal of Nutritional Biochemistry, vol. 24, no. 4, pp. 613-623, 2013.
25. R. A. Harris, T. J. Eichholtz, I. D. Hiles, M. J. Page, and M. J. O'Hare, "New model of ErbB-2 over-expression in human mammary luminal epithelial cells," International Journal of Cancer, vol. 80, no. 3, pp. 477-484, 1999.
26. J. F. Timms, S. L. White, M. J. O'Hare, and M. D. Waterfield, "Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells," Oncogene, vol. 21, no. 43, pp. 6573-6586, 2002.
27. J. M. Seargent, E. A. Yates, and J. H. Gill, "GW9662, a potenteantagonista of PPAR gamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPAR gamma agonist rosiglitazone, independently of PPAR gamma activation," British Journal of Pharmacology, vol. 143, no. 8, pp. 933-937, 2004.
28. R. A. Siddiqui, L. J. Jenski, K. Neff, K. Harvey, R. J. Kovacs, and W. Stillwell, "Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1499, no. 3, pp. 265-275, 2001.
29. T. Martins de Lima, M. F. Cury-Boaventura, G. Giannocco, M. T. Nunes, and R. Curi, "Comparative toxicity of fatty acids on a macrophage cell line (J774)," Clinical Science, vol. 111, no. 5, pp. 307-317, 2006.
30. A. Kourtidis, R. Jain, R.D. Carkner, C. Eifert, M. J. Brosnan, and D. S. Conklin, "An RNA interference screen identifiesmetabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature," Cancer Research, vol. 70, no. 5, pp. 1783-1792, 2010.
31. M. Laplante and D.M. Sabatini, "An emerging role of mTOR in lipid biosynthesis," Current Biology, vol. 19, no. 22, pp. R1046-R1052, 2009.
32. R. Zoncu, A. Efeyan, and D. M. Sabatini, "mTOR: fom growth signal integration to cancer, diabetes and ageing," Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 21-35, 2011.
33. M. Laplante, S. Horvat, W. T. Festuccia et al., "Deptor cellautonomously promotes adipogenesis, and its expression is associated with obesity," Cell Metabolism, vol. 16, no. 2, pp. 202-212, 2012.
34. Z. Wang, J. Zhong, H. Inuzuka et al., "An evolving role for DEPTOR in tumor development and progression," Neoplasia, vol. 14, no. 5, pp. 368-375, 2012.
35. T. R. Peterson, M. Laplante, C. C. Thoreen et al., "DEPTOR is an mTOR inhibitor frequently overexpressed inmultiplemyeloma cells and required for their survival," Cell, vol. 137, no. 5, pp. 873-886, 2009.
36. N. A. O'Brien, K. McDonald, L. Tong et al., "Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT," Clinical Cancer Research, vol. 20, no. 13, pp. 3507-3520, 2014.
37. G. Murali, C. V. Desouza, M. E. Clevenger, R. Ramalingam, and V. Saraswathi, "Differential effects of eicosapentaenoic acid and docosahexaenoic acid in promoting the differentiation of 3T3-L1 preadipocytes," Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 90, no. 1, pp. 13-21, 2014.
38. M. Rossmeisl, D. Medrikova, E. M. Van Schothorst et al., "Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice," Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1841, no. 2, pp. 267-278, 2014.
39. E. Arriola, C. Marchio, D. S. P. Tan et al., "Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines," Laboratory Investigation, vol. 88, no. 5, pp. 491-503, 2008.
40. I. Busmanis, F. Feleppa, A. Jones et al., "Analysis of cerbb2 expression using a panel of 6 commercially available antibodies," Pathology, vol. 26, no. 3, pp. 261-267, 1994.
41. C. Yan, H. Wei, Z. Minjuan et al., "The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells," PLoS ONE, vol. 9, no. 5, Article ID e97697, 2014.
42. R. Porta, A. Blancafort, G. Casoliva et al., "Fatty acid synthase expression is strongly related tomenopause in early-stage breast cancer patients," Menopause, vol. 21, no. 2, pp. 188-191, 2014.
43. C.-L. E. Yen, S. J. Stone, S. Koliwad, C. Harris, and R. V. Farese Jr., "DGAT enzymes and triacylglycerol biosynthesis," Journal of Lipid Research, vol. 49, no. 11, pp. 2283-2301, 2008.
44. A. Bielli, M. G. Scioli, P. Gentile et al., "Adult adipose-derived stem cells and breast cancer: a controversial relationship," Springer Plus, vol. 3, no. 1, pp. 1-10, 2014.
45. E. Hinoi, T. Iezaki, H. Fujita et al., "PI3K/Akt is involved in brown adipogenesismediated by growth differentiation factor-5 in associationwith activation of the Smad pathway," Biochemical and Biophysical Research Communications, vol. 450, no. 1, pp. 255-260, 2014.
46. Z. Zou, C. Bidu, S. Bellenger, M. Narce, and J. Bellenger, "N- 3 polyunsaturated fatty acids and HER2-positive breast cancer: interest of the fat-1 transgenic mouse model over conventional dietary supplementation," Biochimie, vol. 96, no. 1, pp. 22-27, 2014.
47. P. D. Schley, D. N. Brindley, and C. J. Field, "(n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells," Journal of Nutrition, vol. 137, no. 3, pp. 548-553, 2007.
48. K. R. Rogers, K. D. Kikawa, M. Mouradian et al., "Docosahexaenoic acid alters epidermal growth factor receptor-related signaling by disrupting its lipid raft association," Carcinogenesis, vol. 31, no. 9, pp. 1523-1530, 2010.
49. P. A. Corsetto, A. Cremona, G. Montorfano et al., "Chemicalphysical changes in cellmembrane microdomains of breast cancer cells after omega-3 PUFA incorporation," Cell Biochemistry and Biophysics, vol. 64, no. 1, pp. 45-59, 2012.
50. S. Abel, S. Riedel, and W. C. A. Gelderblom, "Dietary PUFA and cancer," Proceedings of the Nutrition Society, vol. 73, no. 3, pp. 361-367, 2014.
51. H.-M. Su, P.-H. Hsieh, and H.-F. Chen, "A maternal high n- 6 fat diet with fish oil supplementation during pregnancy and lactation in rats decreases breast cancer risk in the female offspring," Journal of Nutritional Biochemistry, vol. 21, no. 11, pp. 1033-1037, 2010.
52. P. Bougnoux, N. Hajjaji, and C. Couet, "The lipidome as a composite biomarker of themodifiable part of the risk of breast cancer," Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 79, no. 3-5, pp. 93-96, 2008.
53. L. Hilakivi-Clarke, I. Onojafe, M. Raygada, E. Cho, R. Clarke, and M. E. Lippman, "Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy," Journal of the National Cancer Institute, vol. 88, no. 24, pp. 1821-1827, 1996.
54. H. Vaidya and S. K. Cheema, "Arachidonic acid has a dominant effect to regulate lipogenic genes in 3T3-L1 adipocytes compared to omega-3 fatty acids," Food & Nutrition Research, vol. 59, Article ID 25866, 2015.
55. F. Zhang, Y. Chen, J. Long, L. Dong, Y. Wang, and Y. Chen, "Dietary fatty acids affect lipid metabolism and estrogen receptor expression in N-methyl-N-nitrosourea-induced rat mammary cancer model," Clinical Laboratory, vol. 61, no. 3-4, pp. 389-395, 2015.